The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients

Trial Profile

The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 May 2016

At a glance

  • Drugs Ezetimibe (Primary) ; HMG-CoA reductase inhibitors
  • Indications Dyslipidaemias; Hypercholesterolaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 May 2016 Status changed from recruiting to completed.
    • 16 Sep 2015 Interim results in 58 patients presented at 17th Congress of the European Society for Organ Transplantation.
    • 16 Sep 2015 Status changed from not yet recruiting to recruiting, according to interim results presented at 17th Congress of the European Society for Organ Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top